Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 12/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | PLAT | P00750 | 2/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623755 | 0.89 | NSD2 (0.39) | IKBKBNSD2MAPK1 | |
| SCHEMBL14301889 | 0.74 | AURKA (0.43) | — | |
| SCHEMBL17225065 | 0.73 | KDM4E (0.37) | IKBKBMAPK1 | |
| SCHEMBL1623292 | 0.69 | GPR119 (0.48) | NSD2 | |
| SCHEMBL15602523 | 0.68 | SLC18A3 (0.47) | TLR9TLR8TLR7HRH4NPC1 | |
| SCHEMBL30402943 | 0.67 | L3MBTL1 (0.40) | NSD2MAPK1 | |
| SCHEMBL28287225 | 0.67 | L3MBTL1 (0.40) | NSD2MAPK1 | |
| SCHEMBL21590196 | 0.66 | NOS2 (0.50) | IKBKB | |
| SCHEMBL15407930 | 0.65 | IKBKB (0.39) | IKBKBCHUKHRH4CHRNB4CHRNA3 | |
| SCHEMBL8401200 | 0.64 | L3MBTL1 (0.49) | IKBKBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1876178-B1 | CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-7928126-B2 | Cyanopyridine derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-04-19 | — | — | US | disclosed |
| US-20090292121-A1 | Cyanopyridine derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-1876178-A1 | CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292121-A1 | Cyanopyridine derivative and use thereof as medicine | DPYD, IDH1, TP53 | IKBKB 2286/4885CHUK 1230/4885PLAT 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.